Q1 EPS Estimates for Beta Bionics Reduced by Leerink Partnrs

Beta Bionics, Inc. (NASDAQ:BBNX - Free Report) - Stock analysts at Leerink Partnrs dropped their Q1 2025 earnings per share estimates for shares of Beta Bionics in a research note issued on Wednesday, March 26th. Leerink Partnrs analyst M. Kratky now forecasts that the company will earn ($0.51) per share for the quarter, down from their previous estimate of ($0.50). Leerink Partnrs has a "Strong-Buy" rating on the stock. Leerink Partnrs also issued estimates for Beta Bionics' Q3 2025 earnings at ($0.42) EPS, Q4 2025 earnings at ($0.39) EPS, FY2025 earnings at ($1.83) EPS and FY2027 earnings at ($2.27) EPS.

Other research analysts also recently issued research reports about the stock. Leerink Partners started coverage on shares of Beta Bionics in a research report on Monday, February 24th. They set an "outperform" rating and a $28.00 price objective on the stock. Robert W. Baird started coverage on Beta Bionics in a report on Thursday, February 20th. They set a "neutral" rating and a $20.00 price target on the stock. Lake Street Capital initiated coverage on Beta Bionics in a report on Monday, February 24th. They issued a "buy" rating and a $30.00 price objective for the company. LADENBURG THALM/SH SH began coverage on shares of Beta Bionics in a research note on Thursday, February 20th. They issued a "neutral" rating and a $20.00 price objective on the stock. Finally, Stifel Nicolaus initiated coverage on Beta Bionics in a report on Monday, February 24th. They issued a "buy" rating and a $25.00 target price on the stock. Three equities research analysts have rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, Beta Bionics currently has an average rating of "Moderate Buy" and an average price target of $24.83.

Remove Ads

Beta Bionics Stock Performance

BBNX traded down $0.57 during midday trading on Friday, hitting $11.67. 117,216 shares of the company traded hands, compared to its average volume of 492,332. The firm has a 50-day moving average of $18.60. Beta Bionics has a 52 week low of $11.29 and a 52 week high of $24.50.

Beta Bionics (NASDAQ:BBNX - Get Free Report) last announced its quarterly earnings results on Tuesday, March 25th. The company reported ($1.82) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.42) by ($1.40). The firm had revenue of $20.44 million during the quarter, compared to analysts' expectations of $20.01 million.

Insider Buying and Selling at Beta Bionics

In related news, major shareholder Hadley Harbor Aggre Wellington acquired 1,000,000 shares of the business's stock in a transaction on Friday, January 31st. The stock was acquired at an average cost of $17.00 per share, with a total value of $17,000,000.00. Following the acquisition, the insider now directly owns 3,901,599 shares in the company, valued at $66,327,183. This represents a 34.46 % increase in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, insider Mike Mensinger bought 33,350 shares of the stock in a transaction dated Friday, January 31st. The stock was bought at an average cost of $17.00 per share, for a total transaction of $566,950.00. Following the acquisition, the insider now directly owns 59,019 shares of the company's stock, valued at approximately $1,003,323. This represents a 129.92 % increase in their position. The disclosure for this purchase can be found here.

About Beta Bionics

Beta Bionics, Inc is a commercial-stage medical device company. It engages in the design, development, and commercialization of solutions for insulin-requiring people with diabetes. The company was founded by Edward R. Damiano on October 21, 2015 and is headquartered in Irvine, CA.